This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignees: Centre Hospitalier Regional Universitaire De Brest, Centre National De La Recherche Scientifique, Institut Curie. Active years: 2022.
Company Filing History:
1 out of 1 
1 out of 5,383 
1 out of 161 
Years Active: 2022
Title: Cécile Voisset: Innovator in Cancer Treatment
Introduction
Cécile Voisset is a notable inventor based in Brest, France. He has made significant contributions to the field of cancer treatment, particularly in relation to Epstein-Barr Virus (EBV)-related cancers. His innovative work has led to the development of novel compounds that hold promise for therapeutic applications.
Latest Patents
Cécile Voisset holds a patent for "Hydrazone derivatives for preventing or treating EBV-related cancers." This invention relates to bis-hydrazone derivatives of a specific formula, which are designed to be effective in treating or preventing cancers associated with the Epstein-Barr Virus. The patent outlines the chemical structure and potential applications of these compounds, emphasizing their utility as drugs.
Career Highlights
Throughout his career, Cécile Voisset has been associated with prestigious institutions such as the University Paris XIII and the Centre Hospitalier Régional Universitaire de Brest. His work in these organizations has contributed to advancements in medical research and drug development.
Collaborations
Cécile Voisset has collaborated with notable colleagues, including Anton Granzhan and Alicia Quillevere. These partnerships have fostered a collaborative environment that enhances research and innovation in the field of cancer treatment.
Conclusion
Cécile Voisset's contributions to the development of bis-hydrazone derivatives represent a significant advancement in the fight against EBV-related cancers. His innovative approach and collaborative efforts continue to pave the way for future breakthroughs in cancer therapy.